CorFlow Therapeutics AG

CorFlow Therapeutics is a clinical-stage medical device company headquartered in Baar, Switzerland, focused on transforming the diagnosis and treatment of microvascular obstruction (MVO) in heart attack patients. The company has developed the Controlled Flow Infusion (CoFI) System, a proprietary platform designed to diagnose MVO in real-time during percutaneous coronary intervention (PCI) and enable the localized delivery of therapeutic agents directly to the microvasculature. By addressing the critical unmet need of MVO, which affects more than half of acute STEMI heart attack patients and is a key indicator of heart failure and mortality, CorFlow aims to improve patient outcomes. The company is currently advancing its technology through pivotal clinical trials, including the MOCA II study, and maintains research collaborations with academic institutions such as the University of Bern and ETH Zurich.